1. Home
  2. LMB vs IOVA Comparison

LMB vs IOVA Comparison

Compare LMB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Limbach Holdings Inc.

LMB

Limbach Holdings Inc.

HOLD

Current Price

$93.10

Market Cap

914.9M

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.73

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMB
IOVA
Founded
1901
2007
Country
Employees
N/A
838
Industry
Engineering & Construction
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
914.9M
1.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LMB
IOVA
Price
$93.10
$2.73
Analyst Decision
Strong Buy
Buy
Analyst Count
2
12
Target Price
$130.00
$10.45
AVG Volume (30 Days)
143.2K
10.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$27.83
$60.71
Revenue Next Year
$13.63
$59.35
P/E Ratio
$30.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$63.02
$1.64
52 Week High
$154.05
$6.09

Technical Indicators

Market Signals
Indicator
LMB
IOVA
Relative Strength Index (RSI) 59.85 57.03
Support Level $86.97 $2.47
Resistance Level $97.00 $2.68
Average True Range (ATR) 5.45 0.18
MACD 0.43 0.01
Stochastic Oscillator 76.34 84.75

Price Performance

Historical Comparison
LMB
IOVA

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: